Selected publications

  • 2017
  • Moritz Schütte et al.# (Published 10 Feb 2017)
    Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
    Nature communications. doi: 10.1038/ncomms14262
  • Valenti G, Quinn HM, Heynen GJ, Lan L, Holland JD, Vogel R, Wulf-Goldenberg A, Birchmeier W.
    Cancer stem cells regulate cancer-associated fibroblasts via activation of Hedgehog signaling in mammary gland tumors. Cancer Res. 2017 Feb 15. pii: canres.3490.2015. doi: 10.1158/0008-5472.CAN-15-3490. [Epub ahead of print]
  • 2016
  • Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, Zhang X, Goblirsch M, Wulf-Goldenberg A, Ohtsuka M, Haybaeck J, Svoboda M, Okugawa Y, Gerger A, Hoefler G, Goel A, Slaby O, Calin GA.
    Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
    Clin Cancer Res. 2016 Sep 6. doi: 10.1158/1078-0432.CCR-16-0497. [Epub ahead of print]
  • Natalya Beglyarova, Eugenia Banina,Yan Zhou, Ramilia Mukhamadeeva, Grigorii Andrianov, Egor Bobrov, Elena Lysenko1, Natalya Skobeleva, Linara Gabitova, Diana Restifo, Max Pressman, Ilya G. Serebriiskii, John P. Hoffman, Keren Paz, Diana Behrens, Vladimir Khazak, Sandra A. Jablonski, Erica A. Golemis, Louis M.Weiner, and Igor Astsaturov (2016)
    Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
    Clim. Cancer Res. 22, 6153
  • Rolff J, Becker M, Merk J, Hoffmann J, Fichtner I. (2016)
    Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts
    Targ Oncol DOI 10.1007/s11523-015-0415-4

  • Orthmann A, Peiker L, Fichtner I, Hoffmann A, Hilger RA, Zeisig R. (2016)
    Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes
    J Biomed Nanotechnol 12, 56-68
  • Behrens D, Rolff J, Hoffmann J. (2016)
    Predictive in vivo models for oncology
    Handb Exp Pharmacol. 2015 Oct 22. PMID: 26489829
  • 2015
  • Fang L, Zhu Q, Neuenschwander M, Specker E, Wulf-Goldenberg A, Weis WI, von Kries JP, Birchmeier W. (2015)
    A small-molecule antagonist of the β-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis
    Cancer Res. 2015 Dec 8. pii: canres.1519.2015. PMID: 26645562 [Epub ahead of print]
  • Knöspel F, Freyer N, Stecklum M, Gerlach JC, Zeilinger K. (2015)
    Periodic harvesting of embryonic stem cells from a hollow-fiber membrane based four-compartment bioreactor
    Biotechnol Prog. 2015 Oct 21. doi: 10.1002/btpr.2182. PMID: 26486457 [Epub ahead of print]
  • Qi J, Yu Y, Akilli Öztürk Ö, Holland JD, Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I, Birchmeier W. (2015)
    New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals
    Gut. 2015 Jul 8. pii: gutjnl-2014-307900. doi: 10.1136/gutjnl-2014-307900. PMID: 26156959
    [Epub ahead of print]
  • Roblek M, Calin M, Schlesinger M, Stan D, Zeisig R, Simionescu M, Bendas G, Borsig L. (2015)
    Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis
    J Control Release 220, 341-347
  • Diaz-Miqueli A, Markelova MR, Lemm M, Fichtner I. (2015)
    Co-localization of CD133/EGFR and antiangiogenic activity drive the antitumor effect of Nimotuzumab and radiation in human GBM U87MG xenografted in mice
    Stem Cells Research, Reviews & Reports 2. ISSN: 2381-9073
  • Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M. (2015)
    Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo
    Oncogenesis 4(2)e 137
  • Testen A, Podlipec R, Mravljak J, Orthmann A, Šentjurc M, Zeisig R, Štrancar J, Koklic T. (2015)
    How perifosine affects liposome-encapsulated drug delivery across a cell barrier
    Therapeutic Delivery 6(4), 423-441
  • Lan L, Holland JD, Qi J, Grosskopf S, Rademann J, Vogel R, Györffy B, Wulf-Goldenberg A, Birchmeier W. (2015)
    Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice
    The EMBO Journal 34(11), 1493-508
  • Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J, Fichtner I. (2015)
    A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option
    International Journal of Cancer 136(12), 2940-2948
  • Stecklum M, Wulf-Goldenberg A, Purfürst B, Siegert A, Keil M, Eckert K, Fichtner I. (2015)
    Cell differentiation mediated by co-culture of human umbilical cord blood stem cells with murine hepatic cells
    In Vitro Cellular & Developmental Biology Animal 51(2), 183-191
  • Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G. (2015)
    Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma
    Blood 125(1), 124-132

  • 2014
  • Sheean ME, McShane E, Cheret C, Walcher J, Mueller T, Wulf-Goldenberg A, Hoelper S, Garratt AN, Krueger M, Rajewsky K, Meijer D, Birchmeier W, Lewin GR, Selbach M, Birchmeier C. (2014)
    Activation of MAPK overrides the termination of myelin growth and replaces Nrg1/ErbB3 signals during Schwann cell development and myelination
    Genes & Development 28(3), 290-303
  • Hoffmann J. (2014)
    Integrative oncology drug discovery accompanied by preclinical translational research as prerequisite for clinical development
    Chinese Clinical Oncology 3(2), 15
  • Hülsmann HJ, Rolff J, Bender C, Jarahian M, Korf U, Herwig R, Fröhlich H, Thomas M, Merk J, Fichtner I, Sültmann H, Kuner R. (2014)
    Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib
    Lung Cancer 86(2), 151-157
  • Vallespí MG, Pimentel G, Cabrales-Rico A, Garza J, Oliva B, Mendoza O, Gomez Y, Basaco T, Sánchez I, Calderón C, Rodriguez JC, Markelova MR, Fichtner I, Astrada S, Bollati-Fogolín M, Garay HE, Reyes O. (2014)
    Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models
    Journal of Peptide Science 20(11), 850-859
  • Walther W, Fichtner I, Hackenberg F, Streciwilk W, Tacke M. (2014)
    In vitro and In vivo investigations into the carbene copper bromide anticancer drug candidate WBC4
    Letters in Drug Design & Discovery 11(7), 825-832
  • Belz K, Schoeneberger H, Wehner S, Weigert A, Bönig H, Klingebiel T, Fichtner I, Fulda S. (2014)
    Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly
    Blood 124(2), 240-250
  • Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R, Regenbrecht CRA. (2014)
    The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells
    PLOS ONE 9(5), e92596
  • Friesen C, Hormann I, Roscher M, Fichtner I, Alt A, Hilger R, Debatin KM, Miltner E. (2014)
    Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma
    Cell Cycle 13(10), 1560-1570
  • Kobelt D, Aumann J, Schmidt M, Wittig B, Fichtner I, Behrens D, Lemm M, Freundt G, Schlag PM, Walther W. (2014).
    Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector
    Molecular Oncology 8(3), 609-619
  • 2013
  • Stachelscheid H, Wulf-Goldenberg A, Eckert K, Jensen J, Edsbagge J, Bjoerquist P, Rivero M, Strehl R, Jozefczuk J, Prigione A, Adjaye J, Urbaniak T, Bussmann P, Zeilinger K, Gerlach JC. (2013)
    Teratoma formation of human embryonic stem cells in three-dimensional perfusion culture bioreactors
    Journal of Tissue Engineering and Regenerative Medicine 7(9), 729-741
  • Cheret C, Willem M, Fricker FR, Wende H, Wulf-Goldenberg A, Tahirovic S, Nave KA, Saftig P, Haass C, Garratt AN, Bennett DL, Birchmeier C. (2013)
    Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles
    The EMBO Journal 32(14), 2015-2028
  • Holland JD, Győrffy B, Vogel R, Eckert K, Valenti G, Fang L, Lohneis P, Elezkurtaj S, Ziebold U, Birchmeier W. (2013)
    Combined Wnt/b-catenin, Met and CXCL12/CXCR4 signals characterize basal breast cancer and predicts disease outcome
    Cell Reports 5(5), 1214-1227
  • Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J Jr. (2013).
    Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs
    Translational Oncology 6(6), 685-696
  • Walther W, Schmeer M, Kobelt D, Baier R, Harder A, Walhorn V, Anselmetti D, Aumann J, Fichtner I, Schleef M. (2013)
    A 7-year storage report of GMP-grade naked plasmid-DNA: stability-, topology- and in vitro/in vivo functional analysis
    Human Gene Therapy Clinical Development 24(4), 147-153
  • Gries J, Schumacher D, Arand J, Lutsik P, Markelova MR, Fichtner I, Walter J, Sers C, Tierling S. (2013)
    Bi-PROF: Bisulfite profiling of target regions using 454 GS FLX Titanium technology
    Epigenetics 8(7), 765-771
  • Pechańska P, Becker M, Mayr T, Hinzmann B, Adams H-P, Klaman I, Kretschmar K-H, Kretschmar K, Stecker K, Mantke R, Pauli R, Pertschy J, Hertel K, Ridwelski K, Hellwig K, Pross M, Radke C, Fichtner I, Hoffmann J, Rosenthal A. (2013)
    Mutation status of KRAS, BRAF, PIK3CA and expression level of AREG and EREG identify responders to cetuximab in a large panel of patient derived colorectal carcinoma xenografts of all four UICC stages
    Journal of Cancer Therapy 4, 678-693
  • Friesen C, Roscher M, Hormann I, Fichtner I, Alt A, Hilger RA, Debatin KM, Miltner E. (2013)
    Cell death sensitization of leukemia cells by opioid receptor activation.
    Oncotarget 4(5), 677-690
  • Walther W, Fichtner I, Deally A, Hogan M, Tacke M. (2013)
    The activity of titanocene T against xenografted caki-1 tumors
    Letters in Drug Design & Discovery 10(5), 375-381
  • Bastian L, Hof J, Pfau M, Fichtner I, Eckert K, Henze G, Prada J, von Stackelberg A, Seeger K, Shalapour S. (2013)
    Synergistic activity of bortezomib and HDACis in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT and NF-κB
    Clinical Cancer Research 19(6), 1445-1457
  • Kratz F, Azab S, Zeisig R, Fichtner I, Warnecke A. (2013)
    Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
    International Journal of Pharmaceutics 441(1-2), 499-506
  • 2012
  • Fichtner I.; Cinatl J.; Michaelis M.; Sanders L.C.; Hilger R.; Kennedy B.N.; Reynolds A.L.; Hackenberg F.; Lally G.; Quinn S.J.; McRae I.; Tacke M.
    In vitro and in vivo investigations into the carbene silver acetate anticancer drug candidate SBC1
    Letters in Drug Design & Discovery 9 (9): 815-822 (2012-11)
  • Dahlmann M.; Sack U.; Herrmann P.; Lemm M.; Fichtner I.; Schlag P.M.; Stein U.
    Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation
    Oncotarget 3 (8): 783-797 (2012-08)
  • Orthmann A; Zeisig R; Suess R; Lorenz D; Lemm M; Fichtner I
    Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result
    Pharmaceutical Research (2012-03-08)
  • Keil M; Siegert A; Eckert K; Gerlach J; Haider W; Fichtner I. (2012)
    Transcriptional expression profile of cultured human embryonic stem cells in vitro and in vivo In Vitro Cellular & Developmental Biology Animal : (2012-02-04)
  • Wulf-Goldenberg A; Keil M; Fichtner I; Eckert K (2012)
    Intrahepatic transplantation of CD34(+) cord blood stem cells into newborn and adult NOD/SCID mice induce differential organ engraftment

    Tissue & Cell 44 (2): 80-86 (2012-04)
  • 2011
  • Winsel S; Sommer A; Eschenbrenner J; Mittelstaedt K; Klar U; Hammer S; Hoffmann J (2011)
    Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells
    PLoS ONE 6 (4): e19273 (2011-04-29)
  • Walther W; Petkov S; Kuvardina ON; Aumann J; Kobelt D; Fichtner I; Lemm M; Piontek J; Blasig IE; Stein U; Schlag PM (2011
    Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors )
    Gene Therapy (2011-10-06)
  • Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U (2011)
    Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer
    Journal of the National Cancer Institute 103 (13): 1018-1036 (2011-07-06)
  • Orthmann A; Fichtner I; Zeisig R (2011)
    Improving the transport of chemotherapeutic drugs across the blood-brain barrier

    Expert Review of Clinical Pharmacology 4 (4): 477-490 (2011-07)
  • Tan WL; Bhattacharya B; Loh M; Balasubramanian I; Akram M; Dong D; Wong L; Thakkar B; Salto-Tellez M; Soo RA; Fichtner I; Iacopetta B; Soong R (2011)
    Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer
    Cancer Biology & Therapy 11 (6): 599-608 (2011-03-15)
  • Bachmeier B; Fichtner I; Killian PH; Kronski E; Pfeffer U; Efferth T (2011)
    Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells
    PLoS ONE 6 (5): e20550 (2011-05-26)
  • Abu Ajaj K; El-Abadla N; Welker P; Azab S; Zeisig R; Fichtner I; Kratz F (2011)
    Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative
    European Journal of Cancer (2011-09-19)
  • Fichtner I; Behrens D; Claffey J; Deally A; Gleeson B; Patil S; Weber H; Tacke M (2011)
    The antiangiogenic and antitumoral activity of titanocene Y* in vivo
    Letters in Drug Design & Discovery 8 (4): 302-307 (2011-05)
  • Wulf-Goldenberg A; Eckert K; Fichtner I (2011)
    Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody

    Cytotherapy 13 (1): 108-113 (2011-01)
  • Bergman AM; Adema AD; Balzarini J; Bruheim S; Fichtner I; Noordhuis P; Fodstad O; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
    Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
    Investigational New Drugs 29 (3): 456-466 (2011-06)
  • Kratz F; Fichtner I; Graeser R
    Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model
    Investigational New Drugs (2011-05-18)
  • Merk,J., Rolff,J., Dorn,C., Leschber,G., and Fichtner,I. (2011).
    Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 2011 Mar 17. MID: 21420313 [PubMed - as supplied by publisher]
  • 2010
  • Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J. (2010)
    Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer
    Clinical Cancer Research 16 (5): 1452-1465 (2010-03-01)
  • Brueckner,B., Rius,M., Rivera M., Fichtner,I., Hals,P.A., Sandvold,M.L., and Lyko,F. (2010).
    Delivery of 5-Azacytidine to Human Cancer Cells by Elaidic Acid Esterification Increases Therapeutic Drug Efficacy. Mol Cancer Ther 9, 1256-1264
  • Wenzel,J., Zeisig,R., Haider,W., Habedank,S., and Fichtner,I. (2010).
    Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation. Breast Cancer Res Treat 121, 13-22.
  • 2009
  • Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U (2009).
    Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases
    Neuro Oncology 11 (2): 158-166 (2009-04)
  • 2008
  • Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J (2008)
    Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers
    Clinical Cancer Research 14 (20): 6456-6468 (2008-10-15)
  • 2006
  • Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA (2006).
    MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
    Molecular Immunology 43: 1129-1143 (2006-01-01)
  • 2004
  • Fichtner I; Slisow W; Gill J; Becker M; Elbe B; Hillebrand T; Bibby M (2004).
    Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas
    European Journal of Cancer 40: 298-307 (2004-01-01)
  • Fichtner I; Becker M; Zeisig R; Sommer A (2004).
    In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance
    European Journal of Cancer 40: 845-851 (2004-01-01)
  • 2000
  • Borgmann A; Baldy C; von Stackelberg A; Beyermann B; Fichtner I; Nuernberg P; Henze G (2000).
    Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice
    Pediatric Hematology and Oncology 17: 635-650 (2000-12-01)
  • 1999
  • Hoffmann J; Schmidt-Peter P; Haensch W; Naundorf H; Bunge A; Becker M; Fichtner I (1999).
    Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas
    Clinical Cancer Research 5: 2198-2204 (1999-08-01)

RELATED

2017 © EPO Berlin-Buch GmbH